Circassia Pharmaceuticals Plc US launch of Duaklir at CHEST 2019 (4647Q)
21 October 2019 - 5:00PM
UK Regulatory
TIDMCIR
RNS Number : 4647Q
Circassia Pharmaceuticals Plc
21 October 2019
Circassia Announces Duaklir(R) US Launch at American College of
Chest Physicians' CHEST Annual Meeting 2019
Ø Duaklir(R) launch expands Circassia's US portfolio of COPD
products alongside Tudorza(R)
Oxford, UK and Morrisville, NC, United States - 21 October 2019:
Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE:
CIR), a specialty pharmaceutical company focused on respiratory
disease, today announces the US launch of Duaklir(R) for the
maintenance treatment of chronic obstructive pulmonary disease
(COPD) at the American College of Chest Physicians' CHEST Annual
Meeting 2019, which is currently ongoing in New Orleans, LA.
Duaklir(R) is a fixed-dose LAMA / LABA combination of the
long-acting muscarinic antagonist (LAMA) aclidinium bromide and
long-acting beta-agonist (LABA) formoterol fumarate administered
twice-daily via the breath-actuated, multi-dose inhaler
Pressair(R). Circassia will promote Duaklir(R) in the United States
via its dedicated COPD sales force, alongside its established COPD
treatment Tudorza(R) (aclidinium bromide).
Duaklir(R) has been approved by the United States Food and Drug
Administration based on a broad clinical database. This includes
data from three phase III studies, ACLIFORM, AUGMENT and AMPLIFY,
and the phase IV ASCENT study, which shows aclidinium therapy is
effective at reducing COPD exacerbations. As part of its Duaklir(R)
launch activities at the CHEST Annual Meeting 2019, Circassia
hosted a Respiratory Educational Reception. This brought together
posters presented at major scientific meetings in the United States
and Europe detailing results from the AMPLIFY and ASCENT
studies.
Steve Harris, Circassia's Chief Executive, said: "The US launch
of Duaklir(R) represents a major strategic milestone for Circassia,
significantly boosting our portfolio of marketed respiratory
products and strengthening our offering of COPD treatments
alongside our aclidinium monotherapy, Tudorza(R). With the LAMA /
LABA market predicted to grow strongly in the United States in the
coming years, Duaklir(R) has the opportunity to make an important
contribution to the treatment of this serious disease. We look
forward to our dedicated COPD commercial team successfully
introducing this new therapeutic option, as we make Duaklir(R)
available across the United States."
About COPD
COPD (chronic obstructive pulmonary disease) is a progressive
life-threatening lung disease associated primarily with tobacco
smoke, with other risk factors including exposure to air pollution
or occupational dusts and fumes. The most common symptoms of COPD
are breathlessness, chronic cough and mucous production. COPD
causes serious long-term disability and early death, and the number
of people dying from the disease is growing. According to the
American Lung Association, more than 11 million people have been
diagnosed with COPD and it is the third leading cause of death from
disease in the United States.
Contacts
Circassia
Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405
560
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Dr Christopher Golden Tel: +44 (0) 20 7418
8900
finnCap (Joint Broker)
Geoff Nash / Alice Lane Tel: +44 (0) 20 7220 0500
Numis Securities (Joint Broker)
James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000
FTI Consulting
Simon Conway / Ciara Martin Tel: +44 (0) 20 3727 1000
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. The Company sells its
market-leading NIOX(R) asthma management products directly to
specialists in the United States, United Kingdom, China, Germany
and Italy, and in a wide range of other countries through its
network of partners. In the United States, Circassia has the
commercial rights to chronic obstructive pulmonary disease (COPD)
treatments Tudorza(R) and Duaklir(R). Circassia also has the US and
Chinese commercial rights to the late-stage ventilator-compatible
nitric oxide product LungFit PH. For more information please visit
www.circassia.com.
Duaklir(R) and Tudorza(R) are registered trademarks of Almirall
S.A.
Pressair(R) is a registered trade mark of the AstraZeneca group
of companies
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFSLIELIFIA
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024